1.Primary synovial sarcoma of lung: a clinicopathological analysis of 12 cases.
X W ZHANG ; J G WEI ; J P SUN ; Z G XU ; Q CHENG ; L ZHANG ; L F KONG
Chinese Journal of Pathology 2023;52(11):1120-1125
Objective: To investigate the clinicopathological features, immunophenotype, molecular features and differential diagnosis of primary synovial sarcoma of the lung (PSSL). Methods: Twelve cases of PSSL were collected at Henan Provincial People's Hospital, during May 2010 and April 2021, and their clinicopathological parameters were summarized. SS18-SSX, H3K27Me3, and SOX2 were added to the original immunomarkers to evaluate their diagnostic value for PSSL. Results: The age of 12 patients when diagnosed ranged from 32 to 75 years (mean of 50 years). There were 7 males and 5 females, 2 left lung cases and 10 right lung cases. Of the 6 patients who underwent surgical resection, five cases were confined to lung tissue (T1), one case had mediastinal invasion (T3), two cases had regional lymph node metastasis (N1), and none had distal metastasis. Microscopically, 11 cases showed monophasic spindle cell type and one case showed biphasic type composed of mainly epithelial cells consisting of cuboidal to columnar cells with glandular and cribriform structures. It was difficult to make the diagnosis by using the biopsy specimens. Immunohistochemistry (IHC) showed CKpan expression in 8 of 12 cases; EMA expression in 11 of 12 case; TLE1 expression in 8 of 12 cases; S-100 protein expression in two of 12 cases; various expression of bcl-2 and vimentin in 12 cases, but no expression of SOX10 and CD34 in all the cases. The Ki-67 index was 15%-30%. The expression of SS18-SSX fusion antibody was diffusely and strongly positive in all 12 cases. SOX2 was partially or diffusely expressed in 8 of 12 cases, with strong expression in the epithelial component. H3K27Me3 was absent in 3 of 12 cases. SS18 gene translocation was confirmed by fluorescence in situ hybridization (FISH) test in all 12 samples. Six cases underwent surgery and postoperative chemotherapy, while the other six cases had chemotherapy alone. Ten patients were followed up after 9-114 months, with an average of 41 months and a median of 26 months. Five patients survived and five died of the disease within two years. Conclusions: PSSL is rare and has a broad morphological spectrum. IHC and molecular tests are needed for definitive diagnosis. Compared with current commonly used IHC markers, SS18-SSX fusion antibody has better sensitivity to PSSL, which could be used as an alternative for FISH, reverse transcription-polymerase chain reaction or next generation sequencing in the diagnosis of PSSL.
Male
;
Female
;
Humans
;
Adult
;
Middle Aged
;
Aged
;
Biomarkers, Tumor/analysis*
;
Sarcoma, Synovial/diagnosis*
;
In Situ Hybridization, Fluorescence
;
Histones/genetics*
;
Proto-Oncogene Proteins/metabolism*
;
Oncogene Proteins, Fusion/genetics*
;
Repressor Proteins/metabolism*
;
Lung/pathology*
;
Lung Neoplasms
5.Expressions of HELQ and RAD51C in endometrial stromal sarcoma and their clinical significance.
Ying LIU ; Yu ZHANG ; Yan TIAN
Journal of Zhejiang University. Medical sciences 2020;40(7):936-941
OBJECTIVE:
To observe the expression of HELQ and RAD51C in normal endometrial and endometrial stromal sarcoma (ESS) and analyze their correlation with the clinical features of the patients.
METHODS:
The expressions of HELQ and RAD51C proteins were detected by immunohistochemical staining in normal endometrial tissues (14 cases) and tumor tissues from patients with ESS (37 cases) treated in Hunan Provincial Cancer Hospital from January, 2013 to December, 2016. The correlations of the expressions of the two proteins with the patients'age, FIGO staging, tissue type, tumor size, and lymph node metastasis were analyzed.
RESULTS:
Immunohistochemical staining showed that the expressions of HELQ and RAD51C were both decreased in ESS patients compared with the normal group, and there was a positive correlation between HELQ and RAD51C expression ( < 0.05). HELQ expression in ESS was correlated with the tumor size and type. The expressions of HELQ and RAD51C were not correlated with the patients' age, FIGO stage and status of lymph node metastasis ( > 0.05).
CONCLUSIONS
Homologous recombination- directed DNA repair involving HELQ and RAD51C may participate in the occurrence and progression of ESS.
DNA Helicases
;
genetics
;
DNA-Binding Proteins
;
genetics
;
Endometrial Neoplasms
;
diagnosis
;
physiopathology
;
Endometrium
;
physiopathology
;
Female
;
Gene Expression Regulation, Neoplastic
;
Humans
;
Lymphatic Metastasis
;
physiopathology
;
Sarcoma, Endometrial Stromal
;
physiopathology
6.Current Status of Magnetic Resonance Imaging in Patients with Malignant Uterine Neoplasms: A Review.
Yu Ting HUANG ; Yen Ling HUANG ; Koon Kwan NG ; Gigin LIN
Korean Journal of Radiology 2019;20(1):18-33
In this study, we summarize the clinical role of magnetic resonance imaging (MRI) in the diagnosis of patients with malignant uterine neoplasms, including leiomyosarcoma, endometrial stromal sarcoma, adenosarcoma, uterine carcinosarcoma, and endometrial cancer, with emphasis on the challenges and disadvantages. MRI plays an essential role in patients with uterine malignancy, for the purpose of tumor detection, primary staging, and treatment planning. MRI has advanced in scope beyond the visualization of the many aspects of anatomical structures, including diffusion-weighted imaging, dynamic contrast enhancement-MRI, and magnetic resonance spectroscopy. Emerging technologies coupled with the use of artificial intelligence in MRI are expected to lead to progressive improvement in case management of malignant uterine neoplasms.
Adenosarcoma
;
Artificial Intelligence
;
Carcinosarcoma
;
Case Management
;
Diagnosis
;
Endometrial Neoplasms
;
Female
;
Humans
;
Leiomyosarcoma
;
Magnetic Resonance Imaging*
;
Magnetic Resonance Spectroscopy
;
Sarcoma
;
Sarcoma, Endometrial Stromal
;
Uterine Neoplasms*
7.Characterization and predictive value of volume changes of extremity and pelvis soft tissue sarcomas during radiation therapy prior to definitive wide excision
Chengcheng GUI ; Carol D MORRIS ; Christian F MEYER ; Adam S LEVIN ; Deborah A FRASSICA ; Curtiland DEVILLE ; Stephanie A TEREZAKIS
Radiation Oncology Journal 2019;37(2):117-126
PURPOSE: The purpose of this study was to characterize and evaluate the clinical significance of volume changes of soft tissue sarcomas during radiation therapy (RT), prior to definitive surgical resection. MATERIALS AND METHODS: Patients with extremity or pelvis soft tissue sarcomas treated at our institution from 2013 to 2016 with RT prior to resection were identified retrospectively. Tumor volumes were measured using cone-beam computed tomography obtained daily during RT. Linear regression evaluated the linearity of volume changes. Kruskal-Wallis tests, Mann-Whitney U tests, and linear regression evaluated predictors of volume change. Logistic and Cox regression evaluated volume change as a predictor of resection margin status, histologic treatment response, and tumor recurrence. RESULTS: Thirty-three patients were evaluated. Twenty-nine tumors were high grade. Prior to RT, median tumor volume was 189 mL (range, 7.2 to 4,885 mL). Sixteen tumors demonstrated significant linear volume changes during RT. Of these, 5 tumors increased and 11 decreased in volume. Myxoid liposarcoma (n = 5, 15%) predicted decreasing tumor volume (p = 0.0002). Sequential chemoradiation (n = 4, 12%) predicted increasing tumor volume (p = 0.008) and corresponded to longer times from diagnosis to RT (p = 0.01). Resection margins were positive in three cases. Five patients experienced local recurrence, and 7 experienced distant recurrence, at median 8.9 and 6.9 months post-resection, respectively. Volume changes did not predict resection margin status, local recurrence, or distant recurrence. CONCLUSION: Volume changes of pelvis and extremity soft tissue sarcomas followed linear trends during RT. Volume changes reflected histologic subtype and treatment characteristics but did not predict margin status or recurrence after resection.
Cone-Beam Computed Tomography
;
Diagnosis
;
Extremities
;
Humans
;
Linear Models
;
Liposarcoma, Myxoid
;
Pelvis
;
Recurrence
;
Retrospective Studies
;
Sarcoma
;
Tumor Burden
8.Intravascular papillary endothelial hyperplasia (Masson's hemangioma) of the face
Jin Woo HAN ; Jong Hun LEE ; Eun Kyung KIM
Archives of Craniofacial Surgery 2019;20(2):109-111
Intravascular papillary endothelial hyperplasia or Masson's hemangioma is a rare vascular tumor. The reactive proliferation of endothelial cells in this disease mimics other benign or malignant vascular proliferation such as angiosarcoma or Kaposi's sarcoma. It is important to make an accurate distinction to avoid confusion with these malignant tumors. This would facilitate a proper diagnosis, which is essential so that the patient is not subjected to unnecessarily aggressive or inappropriate treatment.
Diagnosis
;
Endothelial Cells
;
Hemangioma
;
Hemangiosarcoma
;
Humans
;
Hyperplasia
;
Sarcoma, Kaposi
9.Characteristics and Treatment Patterns of Patients with Advanced Soft Tissue Sarcoma in Korea
Hyo Song KIM ; Chung Mo NAM ; Suk Yong JANG ; Sun Kyu CHOI ; Minkyung HAN ; Seonmin KIM ; Maria Victoria MONETA ; Sae Young LEE ; Jae Min CHO ; Diego NOVICK ; Sun Young RHA
Cancer Research and Treatment 2019;51(4):1380-1391
PURPOSE: A soft tissue sarcoma (STS) is a rare type of cancer, accounting for 1% of adult solid cancers. The aim of the present study is to determine the incidence of localized and advanced STS in Korean patients, their treatment patterns, and the survival of patients by disease status. MATERIALS AND METHODS: The STS patient cohort was defined using National Health Insurance Service medical data from 2002 to 2015. Incidence, distribution, anatomical location of tumors, survival rates (Kaplan-Meyer survival function) and treatment patterns were analyzed by applying different algorithms to the STS cohort containing localized and advanced STS cases. RESULTS: A total of 7,813 patients were diagnosed with STS from 2007 to 2014, 4,307 were localized STS and 3,506 advanced STS cases. The total incidence of STS was 2.49 per 100,000 person- years: 1.37 per 100,000 person-years for localized STS and 1.12 per 100,000 person-years for advanced STS. The 5-year survival rate after diagnosis was 56.4% for all STS, 82.4% for localized, and 27.2% for advanced STS. Half of the advanced STS patients (49.98%) received anthracycline-containing chemotherapy as initial treatment after diagnosis. CONCLUSION: This study provides insights into localized and advanced STS epidemiology, treatment patterns and outcomes in Korea, which could be used as fundamental data in improving clinical outcomes of STS patients in the future.
Adult
;
Cohort Studies
;
Diagnosis
;
Drug Therapy
;
Epidemiology
;
Humans
;
Incidence
;
Korea
;
National Health Programs
;
Sarcoma
;
Survival Rate
10.Primary Rhabdomyosarcoma of the Breast: Study of Three Cases at One Institution with a Review of Primary Breast Sarcomas
Junyoung SHIN ; Hee Jeong KIM ; Dae Yeon KIM ; Gyungyub GONG ; Kyung Ja CHO
Journal of Pathology and Translational Medicine 2019;53(5):308-316
BACKGROUND: Primary breast sarcoma (PBS) is rare, comprising approximately 1% of breast malignancies. Rhabdomyosarcoma (RMS) accounts for an extremely small proportion of PBSs, often leading to delayed histologic confirmation. METHODS: Upon reviewing Asan Medical Center’s pathology database between 2000 and 2018, 41 PBS cases were retrieved, including three cases of primary RMS of the breast. Their clinicopathological features were analyzed, and the literature related to PBS and primary RMS of the breast was reviewed. RESULTS: We identified three primary breast RMS cases from our institution database, comprising 7.3% of PBS: one case each of spindle cell/sclerosing RMS (ssRMS), alveolar RMS (aRMS), and embryonal RMS (eRMS). All cases involved adolescents or young adults (14, 16, and 25 years, respectively) who underwent mastectomy or radiotherapy and were confirmed using immunohistochemical testing for myogenin, desmin, and myogenic differentiation. The ssRMS patient experienced recurrence at the operation site 4 months post-surgery despite undergoing concurrent chemoradiotherapy. The aRMS patient had multiple metastases at diagnosis and showed FAX3-FOXO1 fusion transcripts; she died 22 months after the diagnosis. The eRMS patient had enlarged axillary lymph nodes; post-radiotherapy, the lesion recurred as multiple metastases to the bone and lung. She died 18 months post-diagnosis. CONCLUSIONS: Our experience on RMS cases suggests that spindle cell or small round cell malignancy in breasts of young female should raise suspicion for the possibility of primary or secondary RMS. To our knowledge, this is the second report of primary breast ssRMS and it may help clinicians who encounter this rare disease in the future.
Adolescent
;
Arm
;
Breast
;
Chemoradiotherapy
;
Chungcheongnam-do
;
Desmin
;
Diagnosis
;
Female
;
Humans
;
Lung
;
Lymph Nodes
;
Mastectomy
;
Myogenin
;
Neoplasm Metastasis
;
Pathology
;
Radiotherapy
;
Rare Diseases
;
Recurrence
;
Rhabdomyosarcoma
;
Sarcoma
;
Young Adult

Result Analysis
Print
Save
E-mail